Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding (RHHBY)
OTHER OTC:RHHBY
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.47Last Year’s EPS
1.43Same Quarter Last Year
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 30, 2025
|% Change Since: 5.89%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
Roche reported strong financial results for 2024 with significant growth in sales and core operating profit. The company successfully managed the decline in COVID-19 sales through robust base business growth and achieved key milestones in both the pharma and diagnostics segments. However, the net income decline due to impairments and challenges in some markets posed concerns. Overall, the sentiment leans positive with a strong pipeline and strategic focus on future growth.Company Guidance
In the call transcript, Roche Group gave comprehensive guidance on their financial performance and strategic outlook for 2024 and beyond. The company reported a 7% growth in group sales, with the base business, excluding COVID-19 impacts, achieving a remarkable 9% increase. The pharma segment grew by 9%, and diagnostics saw an 8% rise. Core operating profit surged by 14%, while the group core operating margin improved by 2.1 percentage points. Core EPS grew by 12% excluding tax effects, and operating free cash flow skyrocketed by 34% to CHF21.2 billion. Roche achieved significant milestones, including EU approval for Vabysmo and advancements in various trials. They anticipate 2025 as a pivotal year, with numerous Phase III readouts and strategic developments in their pipeline. Additionally, they project mid-single digit sales growth and high-single digit core EPS growth for 2025, aiming to increase dividends further.Strong Group Sales and Core Operating Profit Growth
Roche Group sales grew by 7% with a base business growth of 9%, excluding COVID-19. Core operating profit increased by 14% with a 2.1 percentage point rise in core operating margin.
Diagnostics and Pharma Achievements
Pharma sales grew 8% to CHF46.2 billion and diagnostics base business grew 8%. Key approvals and launches included EU approval for Vabysmo pre-filled syringe and the launch of Mass Spectrometry and other diagnostic tools.
Impressive Cash Flow and Dividend Growth
Operating free cash flow increased by 34% to CHF21.2 billion. The dividend was increased for the 38th consecutive year.
Robust Pipeline and R&D Progress
Roche anticipates significant Phase III readouts in 2025, with a strategic focus on new molecular entities and a strong late-stage pipeline.
---
RHHBY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RHHBY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | $38.86 | $39.84 | +2.52% |
| Jul 25, 2024 | $38.54 | $39.56 | +2.65% |
| Feb 01, 2024 | $34.24 | $33.44 | -2.34% |
| Jul 27, 2023 | $38.15 | $37.88 | -0.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roche Holding (RHHBY) report earnings?
Roche Holding (RHHBY) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Roche Holding (RHHBY) earnings time?
Roche Holding (RHHBY) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RHHBY EPS forecast?
RHHBY EPS forecast for the fiscal quarter 2025 (Q2) is 1.47.
---